144240-01-7

Basic information

• Product Name: (2S,3S,4S,5S)-5-amino-2-carbonyl>valinyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
• Synonyms: (2S,3S,4S,5S)-5-amino-2-carbonyl>valinyl>amino>-3,4-dihydroxy-1,6-diphenylhexane
• CAS NO: 144240-01-7
• Molecular Weight: 547.698
• Mol File: 144240-01-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (2S,3S,4S,5S)-5-amino-2-carbonyl>valinyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(CAS DataBase Reference)
• NIST Chemistry Reference: (2S,3S,4S,5S)-5-amino-2-carbonyl>valinyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(144240-01-7)
• EPA Substance Registry System: (2S,3S,4S,5S)-5-amino-2-carbonyl>valinyl>amino>-3,4-dihydroxy-1,6-diphenylhexane(144240-01-7)

Safety Data

• Hazardous Substances Data: 144240-01-7(Hazardous Substances Data)

Upstream product

• 134878-06-1 (2S,3S,4S,5S)-2,5-diamino-1,6-diphenyl-3,4-hexanediol 
• 134807-31-1 N-<carbonyl>valine p-nitrophenyl ester 
• 3731-51-9 2-(Aminomethyl)pyridine 
• 30293-86-8 methyl (S)-(-)-2-isocyanato-3-methylbutyrate 
• 21035-59-6 N-methyl-2-pyridinemethanamine 
• 6306-52-1 L-valine methylester hydrochloride 
• 134807-30-0 N-<carbonyl>valine methyl ester 
• 144163-45-1 (S)-3-Methyl-2-[[methyl-(2-pyridinylmethyl)amino ]carbonyl]aminobutyric acid 
• 134807-29-7 2-<methyl>pyridine 
• 134807-28-6 2-[N-(tert-butoxycarbonyl)aminomethyl]pyridine 

Relevant articles and documents

Symmetry-Based Inhibitors of HIV Protease. Structure-Activity Studies of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol

The structure-activity relationships in two series of novel, symmetry-based inhibitors of HIV protease, the enzyme responsible for maturation of the human immunodeficiency virus, are described.Beginning with lead compounds 3-6, the effect of adding polar, heterocyclic end groups to one or both ends of the symmetric or pseudosymmetric inhibitors was probed.Aqueous solubility was enhanced >1000-fold while maintaining potent inhibition of purified HIV-1 protease and anti-HIV activity in vitro.Pharmacokinetic studies in rats indicated a substantial difference in the absorption properties of mono-ol-based and diol-based inhibitors.The oral bioavailability of inhibitor 19 in rats was 19percent; however, the Cmax obtained failed to exceed the anti-HIV EC50 in vitro.Substantial plasma levels of potent inhibitors of the diol class were not obtained after oral administration in rats; however, the optimal combination of aqueous solubility and in vitro antiviral activity of several inhibitors support their potential use in intravenous therapy.